Japan Cancer Biomarkers Market Report by Profiling Technology, Biomolecule, Cancer Type, Application, End User, and Region 2025-2033
일본의 암 바이오마커 시장 규모는 2024년 12억 5,260만 달러로 추정됩니다. 향후 IMARC Group은 2033년까지 시장 규모가 36억 2,130만 달러에 달하고, 2025년부터 2033년까지 11.2%의 연평균 성장률(CAGR)을 나타낼 것으로 예측했습니다. 암 환자 증가와 성공적인 치료와 환자 예후를 개선하기 위한 효과적인 진단 및 모니터링 도구에 대한 수요가 증가하면서 시장을 주도하고 있습니다.
본 보고서에서 다룬 주요 질문
- 일본의 암 바이오마커 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 발전할 것인가?
- 코로나19가 일본 암 바이오마커 시장에 미치는 영향은?
- 일본의 암 바이오마커 시장, 프로파일링 기술별 분석 현황은?
- 일본 암 바이오마커 시장의 생체분자별 분석은?
- 일본 암 바이오마커 시장의 암종별 시장 현황은?
- 일본 암 바이오마커 시장 용도별 현황은?
- 일본 암 바이오마커 시장의 최종 사용자별 현황은?
- 일본 암 바이오마커 시장의 가치사슬에는 어떤 단계가 있는가?
- 일본의 암 바이오마커 주요 촉진요인과 과제는?
- 일본 암 바이오마커 시장의 구조와 주요 기업은?
- 일본 암 바이오마커 시장에서의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 일본의 암 바이오마커 시장 : 서론
제5장 일본의 암 바이오마커 시장 구도
- 과거 및 현재 시장 동향(2019-2024년)
- 시장 예측(2025-2033년)
제6장 일본의 암 바이오마커 시장 : 프로파일링 기술별 분석
- Omic Technologies
- 이미징 기술
- 면역측정
- 세포유전학
제7장 일본의 암 바이오마커 시장 : 생체분자별 분석
- 유전자 바이오마커
- 단백질 바이오마커
- 당질 바이오마커
제8장 일본의 암 바이오마커 시장 : 암 유형별 분석
제9장 일본의 암 바이오마커 시장 : 용도별 분석
- 진단
- 예측
- 리스크 평가
- Drug Discovery and Development
- 기타
제10장 일본의 암 바이오마커 시장 : 최종사용자별 분석
- 병원
- 학술연구기관
- 외래수술센터(ASC)
- 진단실험실
- 기타
제11장 일본의 암 바이오마커 시장 : 경쟁 구도
- 개요
- 시장 구조
- 시장 기업 포지셔닝
- 주요 성공 전략
- 경쟁 대시보드
- 기업 평가 상한
제12장 주요 기업 개요
제13장 일본의 암 바이오마커 시장 : 업계 분석
- 성장 촉진요인 및 억제요인과 기회
- Porter의 Five Forces 분석
- 밸류체인 분석
제14장 부록
LSH
Japan cancer biomarkers market size reached USD 1,252.6 Million in 2024. Looking forward, IMARC Group expects the market to reach USD 3,621.3 Million by 2033, exhibiting a growth rate (CAGR) of 11.2% during 2025-2033. The increasing cases of cancer, coupled with the rising need for effective diagnostic and monitoring tools to significantly improve the chances of successful treatment and better patient outcomes, are driving the market.
Cancer biomarkers are molecules or substances found in the body that can indicate the presence of cancer or provide information about its characteristics. These biomarkers are typically detected through blood tests, tissue samples, or imaging studies. They play a crucial role in cancer diagnosis, prognosis, and treatment. Biomarkers can include proteins, genes, hormones, or even specific cellular changes. By analyzing their levels or activity, healthcare professionals can identify the type of cancer, its stage, and its potential aggressiveness. This information helps in tailoring treatment plans, monitoring disease progression, and assessing treatment effectiveness. Cancer biomarkers also have a significant impact on personalized medicine, enabling doctors to choose the most appropriate therapies for individual patients. Additionally, they aid in cancer research, facilitating the development of new drugs and therapies. Overall, cancer biomarkers are essential tools in the fight against cancer, contributing to early detection, precise treatment, and improved patient outcomes.
Japan Cancer Biomarkers Market Trends:
The cancer biomarkers market in Japan is driven by several key factors that collectively contribute to its growth and significance in the field of oncology. Firstly, advancements in molecular biology and genomics have paved the way for the identification of novel biomarkers that can aid in early cancer detection and prognosis. Moreover, the increasing prevalence of cancer in Japan is a major driver, as there is a growing need for accurate and efficient diagnostic tools to combat this regional health challenge. Furthermore, the development of targeted therapies and personalized medicine approaches has accentuated the demand for biomarkers. These biomarkers assist in tailoring treatment plans to individual patients, improving the overall efficacy of cancer treatments while minimizing adverse effects. Additionally, the rise in R&D activities in the pharmaceutical and biotechnology sectors has spurred investments in biomarker discovery and validation, further propelling market growth. Moreover, the widespread adoption of liquid biopsy techniques for non-invasive biomarker detection, as they offer a less invasive alternative to traditional tissue biopsies, is expected to drive the cancer biomarkers market in Japan during the forecast period.
Japan Cancer Biomarkers Market Segmentation:
Profiling Technology Insights:
- Omic Technologies
- Imaging Technologies
- Immunoassays
- Cytogenetics
Biomolecule Insights:
- Genetic Biomarkers
- Protein Biomarkers
- Glyco-Biomarkers
Cancer Type Insights:
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
Application Insights:
- Diagnostics
- Prognostics
- Risk Assessment
- Drug Discovery and Development
- Others
End User Insights:
- Hospitals
- Academic and Research Institutions
- Ambulatory Surgical Centers
- Diagnostic Laboratories
- Others
Competitive Landscape:
The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
Key Questions Answered in This Report:
- How has the Japan cancer biomarkers market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the Japan cancer biomarkers market?
- What is the breakup of the Japan cancer biomarkers market on the basis of profiling technology?
- What is the breakup of the Japan cancer biomarkers market on the basis of biomolecule?
- What is the breakup of the Japan cancer biomarkers market on the basis of cancer type?
- What is the breakup of the Japan cancer biomarkers market on the basis of application?
- What is the breakup of the Japan cancer biomarkers market on the basis of end user?
- What are the various stages in the value chain of the Japan cancer biomarkers market?
- What are the key driving factors and challenges in the Japan cancer biomarkers?
- What is the structure of the Japan cancer biomarkers market and who are the key players?
- What is the degree of competition in the Japan cancer biomarkers market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Japan Cancer Biomarkers Market - Introduction
- 4.1 Overview
- 4.2 Market Dynamics
- 4.3 Industry Trends
- 4.4 Competitive Intelligence
5 Japan Cancer Biomarkers Market Landscape
- 5.1 Historical and Current Market Trends (2019-2024)
- 5.2 Market Forecast (2025-2033)
6 Japan Cancer Biomarkers Market - Breakup by Profiling Technology
- 6.1 Omic Technologies
- 6.1.1 Overview
- 6.1.2 Historical and Current Market Trends (2019-2024)
- 6.1.3 Market Forecast (2025-2033)
- 6.2 Imaging Technologies
- 6.2.1 Overview
- 6.2.2 Historical and Current Market Trends (2019-2024)
- 6.2.3 Market Forecast (2025-2033)
- 6.3 Immunoassays
- 6.3.1 Overview
- 6.3.2 Historical and Current Market Trends (2019-2024)
- 6.3.3 Market Forecast (2025-2033)
- 6.4 Cytogenetics
- 6.4.1 Overview
- 6.4.2 Historical and Current Market Trends (2019-2024)
- 6.4.3 Market Forecast (2025-2033)
7 Japan Cancer Biomarkers Market - Breakup by Biomolecule
- 7.1 Genetic Biomarkers
- 7.1.1 Overview
- 7.1.2 Historical and Current Market Trends (2019-2024)
- 7.1.3 Market Forecast (2025-2033)
- 7.2 Protein Biomarkers
- 7.2.1 Overview
- 7.2.2 Historical and Current Market Trends (2019-2024)
- 7.2.3 Market Forecast (2025-2033)
- 7.3 Glyco-Biomarkers
- 7.3.1 Overview
- 7.3.2 Historical and Current Market Trends (2019-2024)
- 7.3.3 Market Forecast (2025-2033)
8 Japan Cancer Biomarkers Market - Breakup by Cancer Type
- 8.1 Breast Cancer
- 8.1.1 Overview
- 8.1.2 Historical and Current Market Trends (2019-2024)
- 8.1.3 Market Forecast (2025-2033)
- 8.2 Lung Cancer
- 8.2.1 Overview
- 8.2.2 Historical and Current Market Trends (2019-2024)
- 8.2.3 Market Forecast (2025-2033)
- 8.3 Colorectal Cancer
- 8.3.1 Overview
- 8.3.2 Historical and Current Market Trends (2019-2024)
- 8.3.3 Market Forecast (2025-2033)
- 8.4 Prostate Cancer
- 8.4.1 Overview
- 8.4.2 Historical and Current Market Trends (2019-2024)
- 8.4.3 Market Forecast (2025-2033)
- 8.5 Stomach Cancer
- 8.5.1 Overview
- 8.5.2 Historical and Current Market Trends (2019-2024)
- 8.5.3 Market Forecast (2025-2033)
- 8.6 Others
- 8.6.1 Historical and Current Market Trends (2019-2024)
- 8.6.2 Market Forecast (2025-2033)
9 Japan Cancer Biomarkers Market - Breakup by Application
- 9.1 Diagnostics
- 9.1.1 Overview
- 9.1.2 Historical and Current Market Trends (2019-2024)
- 9.1.3 Market Forecast (2025-2033)
- 9.2 Prognostics
- 9.2.1 Overview
- 9.2.2 Historical and Current Market Trends (2019-2024)
- 9.2.3 Market Forecast (2025-2033)
- 9.3 Risk Assessment
- 9.3.1 Overview
- 9.3.2 Historical and Current Market Trends (2019-2024)
- 9.3.3 Market Forecast (2025-2033)
- 9.4 Drug Discovery and Development
- 9.4.1 Overview
- 9.4.2 Historical and Current Market Trends (2019-2024)
- 9.4.3 Market Forecast (2025-2033)
- 9.5 Others
- 9.5.1 Historical and Current Market Trends (2019-2024)
- 9.5.2 Market Forecast (2025-2033)
10 Japan Cancer Biomarkers Market - Breakup by End User
- 10.1 Hospitals
- 10.1.1 Overview
- 10.1.2 Historical and Current Market Trends (2019-2024)
- 10.1.3 Market Forecast (2025-2033)
- 10.2 Academic and Research Institutions
- 10.2.1 Overview
- 10.2.2 Historical and Current Market Trends (2019-2024)
- 10.2.3 Market Forecast (2025-2033)
- 10.3 Ambulatory Surgical Centers
- 10.3.1 Overview
- 10.3.2 Historical and Current Market Trends (2019-2024)
- 10.3.3 Market Forecast (2025-2033)
- 10.4 Diagnostic Laboratories
- 10.4.1 Overview
- 10.4.2 Historical and Current Market Trends (2019-2024)
- 10.4.3 Market Forecast (2025-2033)
- 10.5 Others
- 10.5.1 Historical and Current Market Trends (2019-2024)
- 10.5.2 Market Forecast (2025-2033)
11 Japan Cancer Biomarkers Market - Competitive Landscape
- 11.1 Overview
- 11.2 Market Structure
- 11.3 Market Player Positioning
- 11.4 Top Winning Strategies
- 11.5 Competitive Dashboard
- 11.6 Company Evaluation Quadrant
12 Profiles of Key Players
- 12.1 Company A
- 12.1.1 Business Overview
- 12.1.2 Product Portfolio
- 12.1.3 Business Strategies
- 12.1.4 SWOT Analysis
- 12.1.5 Major News and Events
- 12.2 Company B
- 12.2.1 Business Overview
- 12.2.2 Product Portfolio
- 12.2.3 Business Strategies
- 12.2.4 SWOT Analysis
- 12.2.5 Major News and Events
- 12.3 Company C
- 12.3.1 Business Overview
- 12.3.2 Product Portfolio
- 12.3.3 Business Strategies
- 12.3.4 SWOT Analysis
- 12.3.5 Major News and Events
- 12.4 Company D
- 12.4.1 Business Overview
- 12.4.2 Product Portfolio
- 12.4.3 Business Strategies
- 12.4.4 SWOT Analysis
- 12.4.5 Major News and Events
- 12.5 Company E
- 12.5.1 Business Overview
- 12.5.2 Product Portfolio
- 12.5.3 Business Strategies
- 12.5.4 SWOT Analysis
- 12.5.5 Major News and Events
13 Japan Cancer Biomarkers Market - Industry Analysis
- 13.1 Drivers, Restraints, and Opportunities
- 13.1.1 Overview
- 13.1.2 Drivers
- 13.1.3 Restraints
- 13.1.4 Opportunities
- 13.2 Porters Five Forces Analysis
- 13.2.1 Overview
- 13.2.2 Bargaining Power of Buyers
- 13.2.3 Bargaining Power of Suppliers
- 13.2.4 Degree of Competition
- 13.2.5 Threat of New Entrants
- 13.2.6 Threat of Substitutes
- 13.3 Value Chain Analysis
14 Appendix
